Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis

Author： Grima D.   Papaioannou A.   Thompson M.   Pasquale M.   Adachi J.  

Publisher： Springer Publishing Company

ISSN： 0937-941X

Source： Osteoporosis International, Vol.19, Iss.5, 2008-05, pp. : 687-697

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study

By Silverman S.   Watts N.   Delmas P.   Lange J.   Lindsay R.  

Osteoporosis International, Vol. 18, Iss. 1, 2007-01 ,pp. : 25-34

Springer Publishing Company

Access to resources Recommend Favorite

Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women

By Kanis J.   Borgstrom F.   Johnell O.   Jonsson B.  

Osteoporosis International, Vol. 15, Iss. 11, 2004-11 ,pp. : 862-871

Springer Publishing Company

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of First-Line Chemotherapies in Metastatic Colorectal Cancer

By  

Oncology, Vol. 71, Iss. 1-2, 2007-04 ,pp. : 40-48

Karger

Access to resources Recommend Favorite

A French approach to cost-effectiveness analysis?

By Pouvourville Gérard  

The European Journal of Health Economics, Vol. 11, Iss. 6, 2010-12 ,pp. : 521-523

Springer Publishing Company

Access to resources Recommend Favorite

Modeled cost-effectiveness of the experience corps baltimore based on a pilot randomized trial

By Frick Kevin   Carlson Michelle   Glass Thomas   McGill Sylvia   Rebok George   Simpson Crystal   Fried Linda  

Journal of Urban Health: Bulletin of the New York Academy of Medicine, Vol. 81, Iss. 1, 2004-03 ,pp. : 106-117

Springer Publishing Company

Access to resources Recommend Favorite